|
89 Companies |
|
65 Products |
|
65 Products |
|
50 Mechanisms of Action |
|
831 Trials |
|
64145 News |
|
| «12...708709710711712713714715716717718...720721» |
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma (clinicaltrials.gov) - Aug 12, 2013
P4, N=15, Completed, Sponsor: Siriraj Hospital
Not yet recruiting --> Completed
- dorzolamide/timolol / Generic mfg.
Trial completion: Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms (clinicaltrials.gov) - Aug 12, 2013
P=N/A, N=103, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Not yet recruiting --> Completed Not yet recruiting --> Completed
- ||||| Trial initiation date: Shunt Tube Exposure Prevention Study (clinicaltrials.gov) - Aug 8, 2013
P2/3, N=96, Recruiting, Sponsor: Tissue Tech Inc.
Not yet recruiting --> Completed Initiation date: Jun 2012 --> Jun 2013
- |||||| Enrollment open: Shunt Tube Exposure Prevention Study (clinicaltrials.gov) - Aug 8, 2013
P2/3, N=96, Recruiting, Sponsor: Tissue Tech Inc.
Initiation date: Jun 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- Enrollment closed: Confronting Unequal Eye Care in Pennsylvania (clinicaltrials.gov) - Aug 6, 2013
P=N/A, N=206, Active, not recruiting, Sponsor: Wills Eye
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: TVC: Trabeculectomy Versus Canaloplasty (clinicaltrials.gov) - Aug 6, 2013
P=N/A, N=64, Completed, Sponsor: University Eye Hospital, W
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment open: OMT4OHT: Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects (clinicaltrials.gov) - Aug 5, 2013
P=N/A, N=28, Recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| trabodenoson/latanoprost / Rocket Pharma, trabodenoson (INO-8875) / Rocket Pharma
New P2 trial: A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma (clinicaltrials.gov) - Aug 4, 2013
P2, N=110, Recruiting, Sponsor: Inotek Pharmaceuticals Corporation
- ||||| Helios ocular insert (bimatoprost sustained release insert) / AbbVie
New P2 trial: Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Aug 1, 2013
P2, N=126, Recruiting, Sponsor: ForSight Vision5, Inc.
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open: APPEAL-Taiwan: A Study of Bimatoprost 0.01% in the Clinical Setting (clinicaltrials.gov) - Jul 31, 2013
P4, N=400, Recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=40, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- | New P1/2 trial: Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma (clinicaltrials.gov) - Jul 29, 2013
P1/2, N=40, Recruiting, Sponsor: National Centre of Ophthalmology named after academician Zarifa Aliyeva
- Lucentis (ranibizumab) / Roche, Novartis
Trial termination, Surgery: Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery (clinicaltrials.gov) - Jul 24, 2013
P=N/A, N=11, Terminated, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Completed --> Terminated; low recruitment
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, New P3 trial: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Jul 24, 2013
P3, N=350, Recruiting, Sponsor: Novartis Pharmaceuticals
- Clinical: IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI (clinicaltrials.gov) - Jul 21, 2013
P=N/A, N=10, Not yet recruiting, Sponsor: Sensimed AG
- ||| latanoprost / Generic mfg.
Enrollment change: LYNX: Long-Term Non-Interventional Latanoprost Study (clinicaltrials.gov) - Jul 17, 2013
P4, N=150, Active, not recruiting, Sponsor: Pfizer
Completed --> Terminated; low recruitment N=200 --> 150
- | travoprost ophthalmic / Generic mfg.
Trial completion: Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients (clinicaltrials.gov) - Jul 17, 2013
P1, N=25, Completed, Sponsor: Alcon Research
N=200 --> 150 Recruiting --> Completed
- dorzolamide / Generic mfg.
Trial withdrawal, Combination therapy: Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 16, 2013
P3, N=0, Withdrawn, Sponsor: Allergan
Recruiting --> Completed Not yet recruiting --> Withdrawn
- dorzolamide / Generic mfg.
Enrollment change, Combination therapy: Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 16, 2013
P3, N=0, Withdrawn, Sponsor: Allergan
Not yet recruiting --> Withdrawn N=120 --> 0
- |||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open: An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 16, 2013
P4, N=94, Recruiting, Sponsor: Allergan
N=120 --> 0 Not yet recruiting --> Recruiting
- Enrollment change: IOP Fluctuations in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty (clinicaltrials.gov) - Jul 15, 2013
P=N/A, N=20, Recruiting, Sponsor: Sensimed AG
Not yet recruiting --> Recruiting N=10 --> 20
- dorzolamide/latanoprost (ALZ-1101) / Alleanza
Enrollment change: Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma (clinicaltrials.gov) - Jul 15, 2013
P2, N=68, Recruiting, Sponsor: Azienda Ospedaliera Spedali Civili di Brescia
N=10 --> 20 N=96 --> 68
- | Trial completion: Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG (clinicaltrials.gov) - Jul 15, 2013
P=N/A, N=20, Completed, Sponsor: Sensimed AG
N=96 --> 68 Recruiting --> Completed
- |||| AMA0076 / Akari Therap
Trial completion: Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma (clinicaltrials.gov) - Jul 15, 2013
P2, N=82, Completed, Sponsor: Amakem, NV
Recruiting --> Completed Active, not recruiting --> Completed
- |||||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open: A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 10, 2013
P3, N=440, Recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Vyzulta (latanoprostene bunod) / Bausch Health, Nicox
New P3 trial: Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT (clinicaltrials.gov) - Jul 9, 2013
P3, N=130, Recruiting, Sponsor: Bausch & Lomb Incorporated
- ||||| dorzolamide/latanoprost (ALZ-1101) / Alleanza
New P2 trial: Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost (clinicaltrials.gov) - Jul 9, 2013
P2, N=63, Completed, Sponsor: Alleanza Pharmaceuticals, Inc.
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (clinicaltrials.gov) - Jul 8, 2013
P1/2, N=200, Recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting N=160 --> 200
- || Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change: Observational Study of Lumigan (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=387, Completed, Sponsor: Allergan
N=160 --> 200 N=800 --> 387
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: A Study of Lumigan (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=419, Completed, Sponsor: Allergan
N=800 --> 387 Active, not recruiting --> Completed
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Observational Study of Lumigan (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=387, Completed, Sponsor: Allergan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change: A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=2583, Completed, Sponsor: Allergan
Active, not recruiting --> Completed N=3500 --> 2583
- || Enrollment change: Optical Coherence Tomography (OCT) Data Collection Study (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=322, Completed, Sponsor: Heidelberg Engineering GmbH
N=3500 --> 2583 N=250 --> 322
- Trial completion: ASOCT: Comparison of Gonioscopy With Cirrus and Visante (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=54, Completed, Sponsor: Wills Eye
N=250 --> 322 Not yet recruiting --> Completed
- ||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=2583, Completed, Sponsor: Allergan
Not yet recruiting --> Completed Recruiting --> Completed
- ||| Trial completion: Optical Coherence Tomography (OCT) Data Collection Study (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=322, Completed, Sponsor: Heidelberg Engineering GmbH
Recruiting --> Completed Recruiting --> Completed
- | New P1 trial: Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy (clinicaltrials.gov) - Jun 25, 2013
P1, N=16, Recruiting, Sponsor: Croma-Pharma GmbH
- 5-fluorouracil / Generic mfg.
New P2 trial: Transconjunctival Needling Revision Versus Medical Treatment (clinicaltrials.gov) - Jun 24, 2013
P2, N=40, Completed, Sponsor: University of Sao Paulo General Hospital
- Enrollment open: Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy (clinicaltrials.gov) - Jun 24, 2013
P1, N=16, Recruiting, Sponsor: Croma-Pharma GmbH
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: IOP Lowering Effect of PLT Versus SLT in Naiv OAG Patients (clinicaltrials.gov) - Jun 23, 2013
P=N/A, N=210, Recruiting, Sponsor: University of Zurich
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Trial completion: Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma (clinicaltrials.gov) - Jun 23, 2013
P=N/A, N=119, Completed, Sponsor: Carl Zeiss Meditec, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Astigmatism Post-trabeculectomy (clinicaltrials.gov) - Jun 21, 2013
P=N/A, N=52, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Completed Active, not recruiting --> Completed
- |||| latanoprost / Generic mfg., travoprost ophthalmic / Generic mfg.
Trial completion, Monotherapy: Efficacy of Changing to TRAVATAN (clinicaltrials.gov) - Jun 20, 2013
P4, N=190, Completed, Sponsor: Alcon Research
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Combigan (brimonidine tartrate/timolol maleate) / AbbVie
Trial completion: Efficacy and Tolerability of AZARGA (clinicaltrials.gov) - Jun 20, 2013
P4, N=54, Completed, Sponsor: Alcon Research
Recruiting --> Completed Recruiting --> Completed
- | New P4 trial: Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves (clinicaltrials.gov) - Jun 19, 2013
P4, N=88, Recruiting, Sponsor: University of Virginia
- ||| Trial completion: A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=315, Completed, Sponsor: Allergan
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jun 17, 2013
P4, N=94, Recruiting, Sponsor: Allergan
- |||||||||| New P2/3 trial: InnFocus MicroShunt Versus Trabeculectomy Study (clinicaltrials.gov) - Jun 17, 2013
P2/3, N=857, Recruiting, Sponsor: InnFocus Inc.
- Enrollment closed: Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant (clinicaltrials.gov) - Jun 16, 2013
P2, N=55, Active, not recruiting, Sponsor: InnFocus LLC
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change: A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma (clinicaltrials.gov) - Jun 11, 2013
P3, N=120, Recruiting, Sponsor: Allergan
Enrolling by invitation --> Active, not recruiting N=84 --> 120